Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00262678 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Sublingual Fentanyl Tablets in Treatment of Breakthrough Pain in Cancer Patients.
A Phase 3 study of Cancer and Pain, sponsored by Kyowa Kirin Co..
- Completed
- Registry status
- Phase 3
- Development phase
- 1
- Study location
NCT00262678 is a Phase 3 study of Cancer and Pain that has completed, run by Kyowa Kirin Co.. The trial reports 1 study location across 1 state.
The verdict
NCT00262678, a Phase 3 study of Cancer and Pain, has completed, sponsored by Kyowa Kirin Co..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1
- Study location
Study Summary
The purpose of this study is to determine the effectiveness and safety of sublingual fentanyl tablets in relieving breakthrough pain in cancer patients.
Interventions
- DRUG EN3267
Study Locations (1)
North Carolina
- Carolinas Pain Institute - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Start Date | 2005-12 |
| Est. Completion | 2009-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00262678
The ClinicalTrials.gov registry entry for NCT00262678 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Kyowa Kirin Co., which has 25 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which EN3267 is the first listed.
NCT00262678 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT00262678 about?
NCT00262678 is a clinical study titled "Efficacy and Safety of Sublingual Fentanyl Tablets in Treatment of Breakthrough Pain in Cancer Patients.". The purpose of this study is to determine the effectiveness and safety of sublingual fentanyl tablets in relieving breakthrough pain in cancer patients.
What is the current status of trial NCT00262678?
This trial is currently completed. It is a Phase 3 study. The study started on 2005-12. Estimated completion is 2009-01.
What conditions does trial NCT00262678 study?
This clinical trial studies the following conditions: Cancer, Pain.
What interventions are being tested in trial NCT00262678?
The interventions under investigation include: EN3267 (DRUG).
Who is sponsoring clinical trial NCT00262678?
This trial is sponsored by Kyowa Kirin Co., which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00262678 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Spiritual Care or Psychotherapy Versus Palliative Care Alone in Patients With Non-Curative Malignancies
RECRUITING · Phase 3
-
DOAC - Dosing Options in AntiCoagulation Prophylaxis
RECRUITING · Phase 3
-
Abatacept in Immune Checkpoint Inhibitor Myocarditis
RECRUITING · Phase 3
-
Post-Discharge Risk-Based Management in Patients Undergoing High-Risk Elective Major Cancer Operations (PRS II)
RECRUITING · Phase 3
-
A Randomized Controlled Trial of Inhaled Tranexamic Acid for the Treatment of Pulmonary Hemorrhage in Cancer Patients
RECRUITING · Phase 3
-
Evaluation of a Telehealth Oncofertility Care Intervention in Adolescent and Young Adult Cancer Patients
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.